Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

AACR 2023 highlights on advances in the treatment of biliary tract cancer with Robin Kelley

Reporting from AACR 2023, Robin Katie Kelley discusses the phase III KEYNOTE-966 study evaluating the combination of pembrolizumab with gemcitabine and cisplatin versus gem/cis alone in patients with previously untreated advanced biliary tract cancer. Longer overall survival and duration of response validate the role of immune checkpoint inhibition in combination with chemotherapy as first-line treatment option that improves outcomes in these patients.

Abstract: CT008 - Pembrolizumab (pembro) in combination with gemcitabine and cisplatin (gem/cis) for advanced biliary tract cancer (BTC): Phase 3 KEYNOTE-966 study

Simultaneously published in The Lancet

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.